drugset / Trial / NCT06732323
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
Timeline
- Start
- 2025-09-04
- Primary completion
- 2027-06
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Subject | ESG401 | Monoclonal antibody | — | Intravenous |
| Comparator | Eribulin | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |